Low-dose Pimecrolimus, an FDA-approved Calcineurin Inhibitor, Sensitizes Drug-resistant Cancer Cells via Strong P-gp Inhibition

Park, JH; Lee, JS; Shin, JK; Sharma, S; Kim, HS; Yoon, S

Yoon, S (通讯作者),Sungkyunkwan Univ, Sch Pharm, 2066 Seobu Ro, Suwon 16419, Gyeonggi Do, South Korea.

ANTICANCER RESEARCH, 2023; 43 (3): 1103

Abstract

Background/Aim: Co-treatment with calcineurin inhibitors, such as tacrolimus and cyclosporin A, can sensitize chemotherapy-resistant cancer cells with......

Full Text Link